Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes

Claudia Mittendorff; Issam Abu-Taha; Lena Kassler; Tobias Hustedt; Stephanie Wolf; Johannes G Bode; Markus Kamler; Dobromir Dobrev; Anke C Fender

doi:10.1007/s00210-024-03436-6

Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes

Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 16. doi: 10.1007/s00210-024-03436-6. Online ahead of print.

Authors

Affiliations

¹ Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Duisburg, Germany.
² Department of Gastroenterology, Hepatology and Infectious disease, Faculty of Medicine & Düsseldorf University Hospital, Heinrich-Heine-University, Düsseldorf, Germany.
³ Department of Thoracic and Cardiovascular Surgery, University Hospital Essen, Essen, Germany.
⁴ Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, Canada.
⁵ Department of Integrative Physiology, Baylor College of Medicine, Houston, TX, USA.
⁶ Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Duisburg, Germany. anke.fender@uk-essen.de.

PMID: 39283528
DOI: 10.1007/s00210-024-03436-6

Abstract

Thrombin supports coagulation-independent inflammation via protease-activated receptors (PAR). PAR4 is specifically increased in obese human atria, correlating with NLRP3 inflammasome activation. PAR4-mediated NLRP3 inflammasome activation in atrial cardiomyocytes is not known, nor have signaling partners been identified. Thrombin transactivates the hepatocyte growth factor receptor in some cancer cells, so we examined PAR4/c-met cross-talk in atrial cardiomyocytes and its possible significance in obesity. Cardiomyocytes from right atrial appendages (RAA) of obese patients expressed more PAR1 and PAR4 compared to non-obese. In HL-1 atrial cardiomyocytes, thrombin induced caspase-1 auto-activation and IL-1β maturation; IL-1β secretion was evoked by PAR4-activating peptide (AP), but not PAR1-AP. PAR4-AP additionally increased phosphorylated CaMKII-Thr287, mTOR-Ser2481, and Akt-Ser473 while suppressing AMPK-Thr172 phosphorylation. Total kinase levels were largely unaltered. PAR4AP rapidly increased phosphorylated c-met in HL-1 cells and over time also transcriptionally upregulated c-met. The c-met inhibitor SGX-523 abrogated the effects of PAR4-AP on CaMKII/AKT/mTOR phosphorylation but did not affect PAR4-stimulated IL-1β production. Obese human RAA contained more IL-1β, phospho-c-met, and phospho-mTOR than non-obese RAA; CamKII phosphorylation was not modified. Atria from high-fat diet (HFD) versus chow-fed mice also contained more IL-1β, together with higher myeloperoxidase activity, Acta2 mRNA total and phosphorylated c-met; these increases were blunted in PAR4^-/- HFD-fed mice. Thrombin cross-activates c-met via PAR4 in atrial cardiomyocytes. Transactivated c-met contributes partially to PAR4-mediated signaling, but NLRP3 inflammasome activation appears to be largely independent of c-met. Abundance of PAR4 and activated c-met increases with obesity, providing therapeutic targets for management of adiposity-driven AF.

Keywords: Atrial; C-met; Cardiomyocyte; NLRP3 inflammasome; Protease-activated receptor; Thrombin.

Abstract

Grants and funding